(-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-κB and MAPK/ERK Pathway Modulation

Executive Summary: (-)-Arctigenin is a bioactive natural compound that functions as a dual inhibitor of MEK1 (IC50 = 0.5 nM) and iNOS (IC50 = 10 nM), suppressing NF-κB and MAPK/ERK pathways in preclinical models (APExBIO). It demonstrates potent anti-inflammatory, antiproliferative, and antiviral properties, including in vitro HIV-1 replication inhibition (Li et al. 2022). (-)-Arctigenin is insoluble in water and ethanol but dissolves in DMSO at ≥17.2 mg/mL, with solutions not recommended for extended storage. The product (SKU N2399) is supplied at >98% purity with full analytical documentation (HPLC, NMR, MSDS) and recommended for targeted research use. These claims are supported by product QC and recent peer-reviewed studies on tumor-associated macrophage signaling and NF-κB axis targeting.

Biological Rationale

The NF-κB and MAPK/ERK signaling pathways are central to the regulation of immune responses, cellular proliferation, and apoptosis. Dysregulation of these pathways is implicated in cancer, neurodegeneration, and chronic inflammation (Li et al. 2022). In breast cancer, tumor-associated macrophages (TAMs) promote tumor progression by exporting microRNA-660 in extracellular vesicles, which activates the IKKβ/NF-κB p65 axis. Targeted inhibition of this pathway is linked to reduced metastasis and improved prognosis.

Natural product modulators like (-)-Arctigenin provide precise intervention points in these pathways. Their atomic mechanisms and strong in vitro activity profiles position them as valuable tools for dissecting the role of immune and tumor signaling in disease models. For an expanded mechanistic framework and translational context, see (-)-Arctigenin: A Precision Modulator for Tumor-Immune Cr..., which details the compound’s integration with tumor-immune crosstalk. This article extends those insights with new data and product-specific benchmarks.

Mechanism of Action of (-)-Arctigenin

(-)-Arctigenin targets multiple molecular nodes:

• iNOS Inhibition: Suppresses lipopolysaccharide (LPS)-induced iNOS expression by blocking IκBα phosphorylation and p65 nuclear translocation (IC50 = 10 nM). This restricts nitric oxide (NO) production, a pro-inflammatory mediator (APExBIO).
• MEK1 Inhibition: Inhibits mitogen-activated protein kinase kinase 1 (MEK1) with an IC50 of 0.5 nM, disrupting MAPK/ERK signaling and cell proliferation.
• Neuroprotection: Binds kainate receptors, conferring neuroprotective effects in excitotoxicity models.
• NF-κB Pathway Suppression: Prevents activation of the NF-κB pathway, a critical driver of inflammatory gene transcription, especially in microRNA-660-driven TAM signaling (Li et al. 2022).
• Antiviral Activity: Inhibits HIV-1 replication in vitro, supporting its role as an antiviral compound.

For comparison, Harnessing (-)-Arctigenin in Translational Oncology contextualizes these actions in complex disease models. This article updates those findings with benchmarks on iNOS and MEK1 inhibition potency and product-specific data for APExBIO’s N2399 kit.

Evidence & Benchmarks

• (-)-Arctigenin inhibits LPS-induced iNOS expression and NO production in cell-based assays at an IC50 of 10 nM (APExBIO product documentation: source).
• Suppresses MEK1 kinase activity with an IC50 of 0.5 nM, as measured by in vitro kinase assays (APExBIO).
• Blocks NF-κB pathway activation by preventing IκBα phosphorylation and p65 nuclear translocation, which is key in models of TAM-derived microRNA-660-driven breast cancer progression (Li et al. 2022).
• Inhibits HIV-1 replication in vitro, confirming its antiviral potential (APExBIO).
• Shows high purity (>98%) with validated HPLC and NMR profiles (APExBIO Quality Control Data: link).
• Supplied as a solid, insoluble in water and ethanol, but soluble in DMSO at concentrations ≥17.2 mg/mL. Recommended storage is desiccated at -20°C; avoid long-term solution storage (APExBIO).
• KLHL21 downregulation by TAM-derived microRNA-660 activates IKKβ/NF-κB p65 and accelerates breast cancer metastasis, highlighting the translational importance of NF-κB inhibitors (Li et al. 2022).

For further experimental guidance, (-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-... details use-cases in dissecting tumor microenvironment signaling. This article clarifies specific product QC and mechanistic endpoints.

Applications, Limits & Misconceptions

Research Applications:

• Dissecting NF-κB and MAPK/ERK pathway crosstalk in cancer, inflammatory, and neurodegenerative models.
• High-content screening for MEK1/iNOS inhibitors in cellular and biochemical assays.
• Studying TAM-mediated microRNA signaling in breast cancer metastasis (Li et al. 2022).
• Experimental inhibition of HIV-1 replication and assessment of antiviral strategies.

Common Pitfalls or Misconceptions

• (-)-Arctigenin is NOT soluble in water or ethanol; attempts at aqueous formulation without DMSO will fail.
• Long-term storage of DMSO solutions is NOT recommended; compound should be stored desiccated at -20°C.
• Product is for research use only; NOT approved as a therapeutic or diagnostic agent.
• Anti-inflammatory and antiviral effects are demonstrated in vitro and preclinical models only, NOT in approved clinical settings.
• NF-κB and MEK1 inhibition may not fully recapitulate complex in vivo responses, especially in multi-factorial disease models.

For advanced discussion, (-)-Arctigenin in Translational Oncology: Precision Modul... explores the broader implications of pathway inhibition. This article provides explicit compound solubility and storage caveats.

Workflow Integration & Parameters

Preparation & Storage: Reconstitute N2399 (-)-Arctigenin in DMSO (≥17.2 mg/mL). Store powder desiccated at -20°C. Do not store solutions long term. Verify purity and concentration by HPLC or NMR as needed.

Assay Integration: For cell-based studies, dilute DMSO stock into media at a final DMSO concentration ≤0.1% to avoid solvent toxicity. Typical working concentrations: 1–100 nM for MEK1/iNOS inhibition studies. Include appropriate vehicle controls.

Safety: Refer to the product’s MSDS for handling instructions. Use in a chemical fume hood with gloves and eye protection.

For project planning, see (-)-Arctigenin: Novel Insights into MicroRNA-Driven NF-κB... for examples of integrating (-)-Arctigenin into microRNA-driven signaling studies. This article extends those protocols with updated storage, QC, and dose guidance.

Conclusion & Outlook

(-)-Arctigenin (APExBIO N2399) is a robust, well-characterized MEK1 and iNOS inhibitor for research on NF-κB and MAPK/ERK signaling. Its molecular precision and extensive QC make it suitable for dissecting TAM-driven cancer and inflammation models. Future research should validate its effects in more complex disease systems and explore combinatory approaches. For ordering and full technical documentation, refer to the APExBIO product page.